Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MODULO Trial: Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully Treated With Three-drug Regimens at Inclusion

NCT06774872 is registered in ClinicalTrials.gov with Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida as lead sponsor.

NCT NCT06774872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06774872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MODULO Trial: Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully Treated With Three-drug Regimens at Inclusion
Lead sponsor
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2025
Completion date
June 15, 2028
Enrollment
408 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection